These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 17455364)

  • 1. Physical characterization of component particles included in dry powder inhalers. II. Dynamic characteristics.
    Hickey AJ; Mansour HM; Telko MJ; Xu Z; Smyth HD; Mulder T; McLean R; Langridge J; Papadopoulos D
    J Pharm Sci; 2007 May; 96(5):1302-19. PubMed ID: 17455364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physical characterization of component particles included in dry powder inhalers. I. Strategy review and static characteristics.
    Hickey AJ; Mansour HM; Telko MJ; Xu Z; Smyth HD; Mulder T; McLean R; Langridge J; Papadopoulos D
    J Pharm Sci; 2007 May; 96(5):1282-301. PubMed ID: 17455324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
    Zeng XM; MacRitchie HB; Marriott C; Martin GP
    Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved aerosolization performance of salbutamol sulfate formulated with lactose crystallized from binary mixtures of ethanol-acetone.
    Kaialy W; Ticehurst MD; Murphy J; Nokhodchi A
    J Pharm Sci; 2011 Jul; 100(7):2665-84. PubMed ID: 21268026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
    de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
    Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Powder specific active dispersion for generation of pharmaceutical aerosols.
    Crowder T; Hickey A
    Int J Pharm; 2006 Dec; 327(1-2):65-72. PubMed ID: 16930884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate.
    Kaialy W; Ticehurst M; Nokhodchi A
    Int J Pharm; 2012 Feb; 423(2):184-94. PubMed ID: 22197772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dry powder aerosols generated by standardized entrainment tubes from drug blends with lactose monohydrate: 1. Albuterol sulfate and disodium cromoglycate.
    Xu Z; Mansour HM; Mulder T; McLean R; Langridge J; Hickey AJ
    J Pharm Sci; 2010 Aug; 99(8):3398-414. PubMed ID: 20198688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of physical properties and morphology of crystallised lactose on delivery of salbutamol sulphate from dry powder inhalers.
    Kaialy W; Martin GP; Larhrib H; Ticehurst MD; Kolosionek E; Nokhodchi A
    Colloids Surf B Biointerfaces; 2012 Jan; 89():29-39. PubMed ID: 21962946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
    Singh DJ; Jain RR; Soni PS; Abdul S; Darshana H; Gaikwad RV; Menon MD
    J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):254-67. PubMed ID: 25517187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lactose composite carriers for respiratory delivery.
    Young PM; Kwok P; Adi H; Chan HK; Traini D
    Pharm Res; 2009 Apr; 26(4):802-10. PubMed ID: 19015956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elucidating the Effect of Fine Lactose Ratio on the Rheological Properties and Aerodynamic Behavior of Dry Powder for Inhalation.
    Sun Y; Qin L; Li J; Su J; Song R; Zhang X; Guan J; Mao S
    AAPS J; 2021 Apr; 23(3):55. PubMed ID: 33856568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic electrostatic charge of lactose-salbutamol sulphate powder blends dispersed from a Cyclohaler®.
    Hoe S; Young PM; Traini D
    Drug Dev Ind Pharm; 2011 Nov; 37(11):1365-75. PubMed ID: 21554161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of SCF-engineered particle-based lactose blends in passive dry powder inhalers.
    Schiavone H; Palakodaty S; Clark A; York P; Tzannis ST
    Int J Pharm; 2004 Aug; 281(1-2):55-66. PubMed ID: 15288343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Granulated Lactose as a Carrier for Dry Powder Inhaler Formulations 2: Effect of Drugs and Drug Loading.
    Du P; Du J; Smyth HDC
    J Pharm Sci; 2017 Jan; 106(1):366-376. PubMed ID: 27939234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adhesion forces in interactive mixtures for dry powder inhalers--evaluation of a new measuring method.
    Lohrmann M; Kappl M; Butt HJ; Urbanetz NA; Lippold BC
    Eur J Pharm Biopharm; 2007 Sep; 67(2):579-86. PubMed ID: 17418548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of milling and sieving on functionality of dry powder inhalation products.
    Steckel H; Markefka P; teWierik H; Kammelar R
    Int J Pharm; 2006 Feb; 309(1-2):51-9. PubMed ID: 16377105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting the aerosol performance of dry powder inhalation formulations by interparticulate interaction analysis using inverse gas chromatography.
    Tong HH; Shekunov BY; York P; Chow AH
    J Pharm Sci; 2006 Jan; 95(1):228-33. PubMed ID: 16315225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of the lactose grade within dry powder formulations of fluticasone propionate and terbutaline sulphate.
    Le VN; Bierend H; Robins E; Steckel H; Flament MP
    Int J Pharm; 2012 Jan; 422(1-2):75-82. PubMed ID: 22036653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The contribution of different formulation components on the aerosol charge in carrier-based dry powder inhaler systems.
    Hoe S; Traini D; Chan HK; Young PM
    Pharm Res; 2010 Jul; 27(7):1325-36. PubMed ID: 20354768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.